Cholecystokinin-8 vs Linaclotide
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Linaclotide (Linaclotide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | Linaclotide |
|---|---|---|
| Category | Endocrine Peptides | Gastrointestinal |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | Linaclotide |
| Molecular Weight | 1143.2 Da | 1526.8 Da |
| Half-Life | 1-2 min | Active locally; negligible systemic half-life |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | 14 |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | 72-290 mcg once daily |
| Route | endogenous secretion|research IV/SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 1200 |
| Research Status | Endogenous | Clinical |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.